// App-Quantinova.ai

1284 : Lurbinectedin reduces tumor-associated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models

Researchers

Presenter

  • Paola Allavena

Principal Investigators

  • Cristina Belgiovine

  • Manuela Liguori

  • Ezia Bello

  • Roberta Frapolli

  • Carlos M. Galmarini

  • Maurizio DIncalci

Medical Centers

  • Istituto Clinico Humanitas IRCCS, Rozzano (Milan), Italy

  • Istituto Ricerche Farmacologiche "Mario Negri", Milan, Italy

  • Pharmamar SA, Colmenar Viejo, Spain.

Locations

  • Spain

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

  • Fibroblastic sarcoma

  • Liposarcomas

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • C-X-C motif chemokine ligand 8

  • Stromal interaction molecule 1

  • Vascular endothelial growth factor A

Drug/Treatment

  • Lurbinectedin

  • Trabectedin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved